Player Avatar zzlangerhans (99.85) Submitted: 12/7/2011 12:14:33 AM : Underperform Start Price: $5.65 RPTP Score: +8.97

Raptor has sneakily crossed back above my red thumb threshold in the absence of new positive catalysts. The DR Cysteamine NDA won't be filed until Q1 2012 which means we won't be seeing any revenue numbers until at least 2013. I think the traders who sold on positive phase III results had the right idea. DR Cysteamine is more likely to join Nuedexta and Krystexxa than Soliris and Cinryze. Meanwhile, we haven't heard much lately about DR Cysteamine for NASH and Huntington's, or Convivia.

Featured Broker Partners